Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib

Anticancer Research

Volumn 33, Issue 10, 2013, Pages 4619-4626

  Maeng, Chi Hoon ^a,b   Yi, Jun Ho ^a,c   Lee, Jeeyun ^a   Hong, Jung Yong ^a   Choi, Moon Ki ^a   Jung, Hyun Ae ^a   Park, Joon Oh ^a   Park, Se Hoon ^a   Park, Young Suk ^a   Kang, Won Ki ^a   Lim, Ho Yeong ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

Biliary tract cancer; Gastric cancer; Single nucleotide polymorphism; Sunitinib; VEGF; VEGFR

Indexed keywords

DOCETAXEL; SUNITINIB; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ADULT; ADVANCED CANCER; ADVANCED GASTRIC CANCER; AGED; ANEMIA; ARTICLE; BILIARY TRACT CANCER; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TIME TO TREATMENT; TREATMENT FAILURE; TREATMENT OUTCOME;

BILIARY TRACT CANCER; GASTRIC CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SUNITINIB; VEGF; VEGFR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BILIARY TRACT NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENETIC ASSOCIATION STUDIES; HOMOZYGOTE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PYRROLES; STOMACH NEOPLASMS; TREATMENT FAILURE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84891356145     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X and Figlin RA: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590, 2009.
2. George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP and Demetri GD: Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45: 1959-1968, 2009.
3. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R and Ruszniewski P: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364: 501-513, 2011.
4. Xiao YY, Zhan P, Yuan DM, Liu HB, Lv TF, Song Y and Shi Y: Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: A meta-analysis of randomized controlled trials. Eur J Clin Pharmacol, 2012.
5. Spigel DR, Greco FA, Rubin MS, Shipley D, Thompson DS, Lubiner ET, Eakle JF, Quinn R, Burris HA and Hainsworth JD: Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small cell lung cancer. Lung Cancer 77: 359-364, 2012.
6. Baumann KH, du Bois A, Meier W, Rau J, Wimberger P, Sehouli J, Kurzeder C, Hilpert F, Hasenburg A, Canzler U, Hanker LC, Hillemanns P, Richter B, Wollschlaeger K, Dewitz T, Bauerschlag D and Wagner U: A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: A randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann Oncol 23: 2265-2271, 2012.
7. Yi JH, Thongprasert S, Lee J, Doval DC, Park SH, Park JO, Park YS, Kang WK and Lim HY: A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study. Eur J Cancer 48: 196-201, 2012.
8. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM and Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368: 1329-1338, 2006.
9. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM and Figlin RA: Sunitinib versus interferon alpha in metastatic renal cell carcinoma. N Engl J Med 356: 115-124, 2007.
10. Holmes K, Roberts OL, Thomas AM and Cross MJ: Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19: 2003-2012, 2007.
11. Schneider BP, Radovich M and Miller KD: The role of vascular endothelial growth factor genetic variability in cancer. Clin Cancer Res 15: 5297-5302, 2009.
12. Kim JJ, Vaziri SA, Rini BI, Elson P, Garcia JA, Wirka R, Dreicer R, Ganapathi MK and Ganapathi R: Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 118: 1946-1954, 2012.
13. Vaziri SA, Kim J, Ganapathi MK and Ganapathi R: Vascular endothelial growth factor polymorphisms: Role in response and toxicity of tyrosine kinase inhibitors. Curr Oncol Rep 12: 102-108, 2010.
14. Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, Venitz J and Figg WD: The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 8: 2496-2508, 2009.
15. van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, Boven E, van der Straaten T, Baak-Pablo RF, Wessels JA, Guchelaar HJ and Gelderblom H: Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 27: 4406-4412, 2009.
16. Garcia-Donas J, Esteban E, Leandro-Garcia LJ, Castellano DE, del Alba AG, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Mellado B, Martinez E, Moreno F, Font A, Robledo M and Rodriguez-Antona C: Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal cell carcinoma treated with first-line sunitinib: A multicentre, observational, prospective study. Lancet Oncol 12: 1143-1150, 2011.
17. Yi JH, Lee J, Park SH, Park JO, Yim DS, Park YS, Lim HY and Kang WK: Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer 106: 1469-1474, 2012.
18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
19. Rutkowski P, Bylina E, Klimczak A, Switaj T, Falkowski S, Kroc J, Lugowska I, Brzeskwiniewicz M, Melerowicz W, Osuch C, Mierzejewska E, Wasielewski K, Wozniak A, Grzesiakowska U, Nowecki ZI, Siedlecki JA and Limon J: The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study. BMC Cancer 12: 107, 2012.
20. Janowska-Wieczorek A, Majka M, Ratajczak J and Ratajczak MZ: Autocrine/paracrine mechanisms in human hematopoiesis. Stem Cells 19: 99-107, 2001.
21. Kabrun N, Buhring HJ, Choi K, Ullrich A, Risau W and Keller G: Flk-1 expression defines a population of early embryonic hematopoietic precursors. Development 124: 2039-2048, 1997.
22. Bhargava P: VEGF kinase inhibitors: How do they cause hypertension? Am J Physiol Regul Integr Comp Physiol 297: R1-5, 2009.
23. Cohen RB and Oudard S: Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities. Invest New Drugs 30: 2066-2079, 2012.
24. Bamias A, Manios E, Karadimou A, Michas F, Lainakis G, Constantinidis C, Deliveliotis C, Zakopoulos N and Dimopoulos MA: The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer. Eur J Cancer 47: 1660-1668, 2011.
25. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS and Motzer RJ: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103: 763-773, 2011.